NEW YORK (GenomeWeb News) – TAP Biosystems announced today a deal with Life Technologies to combine their technologies to develop a high-throughput protein expression platform.
TAP will combine its ambr advanced micro-bioreactors with Life Tech's Expi293 Expression System for transient transfection, resulting in a platform that will increase consistency and productivity, providing researchers a tool for small volume protein expression screens and optimization of transient expression conditions, it said.
TAP's ambr system uses "realistic" scale down bioreactors where culture conditions are controlled in 48 micro-bioreactors in parallel "so that protein quality produced by the Expi293F cells cultured in ambr is highly consistent," the Cambridge, UK-based company said. Resulting proteins can be used for vector optimization studies and high-throughput, small-scale functional protein production and protein purification research.
The platform being developed "will enable scientists to rapidly automate the generation of enough protein for analysis from 48 parallel cultures, thus saving laboratory staff time, increasing laboratory capacity, and significantly reducing the cost per gram of protein produced," Barney Zoro, ambr product manager for TAP, said in a statement.
Financial and other terms of the deal were not disclosed.
TAP develops automated cell culture and processing systems for bioprocessing, drug discovery, and regenerative medicine applications.